Danny Williams, President of Channel Management & 3PL at EVERSANA, recently sat down Pharmaceutical Commerce for a series of interviews on the state of pharm 3PLs and logistics. He discussed the role of today’s logistics partners and how it is expanding to support more connected, flexible, and strategy‑driven commercialization models.
From Logistics to Strategic Value
A key theme across the discussions is the shift from transactional support to strategic partnership.
3PLs are no longer defined by distribution alone and are expected to integrate more closely with commercialization strategies, enabling speed, visibility, and coordination across the product lifecycle.
Rising Expectations, Greater Complexity
As therapies become more specialized and patient pathways more complex, the demands placed on supply chain partners are increasing.
Clients are prioritizing:
- Greater flexibility and scalability
- Real‑time visibility into operations and performance
- Seamless integration across systems and stakeholders
The conversations also point to the future where 3PLs will play a more central role in helping pharma companies navigate market dynamics and deliver therapies to patients more efficiently.
Explore the Full Video Interview Series
Why pharma 3PLs are rethinking their role in commercialization
What the next five years hold for pharma 3PLs
What pharma looks for in a 3PL partner in 2026
How 3PLs have evolved in recent years
Learn more about EVERSANA’s global 3PL solutions
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…